According to a Calcalist report, the company is set to go private after a $1.1 billion acquisition by a fund.
Stocktwits
Why Did Corcept Therapeutics Stock Surge Over 14% Today?
In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone.
Stocktwits
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb
The company, along with Bristol Myers Squibb, will develop a new tumor-activated therapy.
Stocktwits
Why Did Greenwich LifeSciences Stock Soar Pre-Market Today?
The company disclosed that the Food and Drug Administration (FDA) has reviewed and authorized the use of its first commercially produced batch of the GP2 drug product in the ongoing FLAMINGO-01 trial.
Stocktwits
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?
On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.
Stocktwits
Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond
After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.
Zacks
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.
Zacks
Trump Locks In Drug-Price Cuts With Roche, Novartis, Merck — More Big Pharma Deals Coming Next Week
The deals expand the pricing program to several drugmakers in exchange for temporary tariff relief.
Stocktwits
Trump Steps Up Pressure On Trading Partners Over Drug Costs, Plans Section 301 Review: Report